NSCLC drug market in China set to reach $640M in 2011
The non-small cell lung cancer drug market in China will reach a value of $640.0 million in 2011, says research advisory firm Decision Resources.
According to its new report, titled Non-Small Cell Lung Cancer in China, the emergence of novel monoclonal antibodies - most notably Genentech/Roche's Avastin (bevacizumab) and ImClone/Merck KGaA's Erbitux (cetuximab) - will drive growth. Avastin will be the market leader in China by 2011. Deeper market penetration of recently-available small-molecule epidermal growth factor receptor inhibitors, such as AstraZeneca's Iressa (gefitinib) and Genentech/Roche's Tarceva (erlotinib), will also add to the growth.
The report also finds that domestically-manufactured agents, if available, are more commonly used than their western branded counterparts. In rural China, almost all drugs used are manufactured domestically, whereas in urban areas, patients who can afford higher treatment costs use western brands, which must also compete with traditional Chinese medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze